GlassScriptPhysician profile
Richard S Gold
NPI 1184796310
$11,246.13
in general payments reported to CMS, 2019-2025
52 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,716 · 2020: $957 · 2021: $1,729 · 2022: $1,684 · 2023: $1,889 · 2024: $1,627 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,159.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $961.30 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Glaxosmithkline, LLC. | $828.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $775.02 | 2019-2025 | |
| Amarin Pharma, INC. | $773.24 | 2019-2023 | |
| Novo Nordisk INC | $748.33 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $700.82 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $687.43 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $655.46 | 2019-2025 | Gardasil 9, Dificid, Gardasil |
| Abbvie INC. | $585.22 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $511.43 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $483.66 | 2019-2025 | Jardiance, Emgality, Zepbound |
| Amgen INC. | $462.97 | 2019-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $320.74 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Astellas Pharma US INC | $303.81 | 2019-2025 | Veozah, Myrbetriq |
| Radius Health, INC. | $248.50 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.